Dr. Norbert Struck
Dr. Helga Neidlein
Dr. Peter Roos
Christian von Lettow-Vorbeck
Dr. Dirk Bröcher
Ingo W. Bauer, Ph.D. (WHUT)
Dr. Nils Eichenauer
Dr. Lorenz Obrecht
Dr. Felix Meinel
Teru Koide 小出 輝
Jürgen Dressel, Ph.D. (Ohio St. Univ.)
Dr. Johannes Lüning
Juergen Dressel studied chemistry in Erlangen, Germany, until after his intermediate diploma, then went to The Ohio State University in Columbus, Ohio, USA, on a Fulbright scholarship and received his Ph.D. there in 1987 under Prof. Leo Paquette on 'Through-bond interaction of two mutually perpendicular π-ribbons through a cyclobutane relay ', an organic synthesis topic with physical/theoretical-chemistry aspects.
This was followed by postdoctoral research with Prof. Duilio Arigoni at ETH Zurich on the biosynthesis of ergot alkaloids by feeding radiolabeled potential intermediates to ergot fungi.
From 1988 to 1997, he worked as a medicinal chemist in pharmaceutical research at Bayer AG in Wuppertal, Germany. In addition to drug synthesis for research and development projects in the fields of cardiovascular and CNS diseases, he also chemically supervised the basic research working group CNS for the identification and evaluation of new, drug therapy approaches. He is named as an inventor on numerous patents.
After joining the pharmaceutical group of Bayer's patent and licensing department, he qualified as an authorized representative before the European Patent Office in 2000 (mentor Peter Roos). Among other things, he drafted patent applications in the pharmaceutical field, conducted international patent examination proceedings, did patent portfolio analysis and optimization for Bayer drugs, finally coordinated the defense of the Viagra® competitor Levitra® against a dominant second medical use patent of Pfizer at the EPO, in Brazil and Mexico.
In 2002, he joined Novartis' Generics Patent Group in Basel, where he prepared freedom-to-operate analyses and strategies for generic compounds and led invalidity and infringement proceedings in various European countries and Argentina.
In 2004, he moved to the originator area of the Novartis patent department where he became Head of Primary Care Patents responsible for all Novartis therapeutic areas except oncology with patent attorneys in several locations in Switzerland, USA, UK and Austria. As Head of Global Patent Litigation ex US he then coordinated international patent litigation outside the US within Novartis Pharma, and as Head of Global Patent Litigation Strategy in Pharma he supported the preparation of international patent litigation.
He has lectured on and discussed patent topics at many international patent conferences, organized multidisciplinary conferences on second medical use patents in collaboration with generic drug manufacturer Teva and Sir Robin Jacob, former judge at the Court of Appeal in London, served as a member of the supervisory board of the Max Planck Institute for Innovation and Competition, and is vice president of the Arbeitskreis Patentgerichtswesen in Deutschland e.V., which aims to make important patent decisions available in English, especially those of the German Federal Court of Justice. In 2013, he was named one of the Top 50 Most Influential People in IP by Managing Intellectual Property magazine.
He retired in 2019 and is a freelance consultant in the field of patent litigation.